FNY Investment Advisers’s Cardiff Oncology CRDF Stock Holding History

FNY Investment Advisers’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,000	Closed	-$7K	–	986
2019 Q1	$7K	Buy	+2,000	New	+$7.15K	﹤0.01%	480

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FNY Investment Advisers's CRDF Position: Q2 2019 in Review

FNY Investment Advisers sold out of Cardiff Oncology (CRDF) in Q2 2019, closing a stake of 2,000 shares — an estimated $7K sold.

FNY Investment Advisers first reported a position in CRDF in Q1 2019 and held it in 1 quarter. The position peaked at $7K in Q1 2019. 23 funds tracked by Wall St. Rank hold CRDF as of Q2 2019.

FNY Investment Advisers reported no remaining Cardiff Oncology position as of Q2 2019 after selling out during the quarter.
FNY Investment Advisers sold 2,000 Cardiff Oncology shares in Q2 2019, an estimated $7K.
FNY Investment Advisers first reported a position in Cardiff Oncology in Q1 2019 and held it in 1 quarter.
FNY Investment Advisers's Cardiff Oncology position peaked at $7K in Q1 2019.
23 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2019.

Based on FNY Investment Advisers's 13F filing for Q2 2019, filed 24 Jul 2019.